A5065755796- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Colorectal and Anal Carcinomas
- Pancreatic and Hepatic Oncology Research
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Gastrointestinal Tumor Research and Treatment
- Immunotherapy and Immune Responses
- Study of Mite Species
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Soft tissue tumor case studies
- Dermatological diseases and infestations
- Immune Cell Function and Interaction
- Gas Sensing Nanomaterials and Sensors
- Invertebrate Immune Response Mechanisms
- Cancer Diagnosis and Treatment
- Plant and Fungal Interactions Research
- CRISPR and Genetic Engineering
- Colorectal Cancer Screening and Detection
Peking University
2015-2024
Peking University Cancer Hospital
2017-2024
Ministry of Education
2020-2024
Qingdao University
2024
Nanjing Forestry University
2024
China University of Mining and Technology
2023
Shenyang Sinochem Agrochemicals R&D Co., Ltd. (China)
2017
Sinochem Group (China)
2017
Xi'an Jiaotong University
2012-2013
Abstract Despite success in hematologic malignancies, the treatment landscape of chimeric antigen receptor (CAR) T cell therapy for solid tumors remains limited. Claudin18.2 (CLDN18.2)-redirected CAR cells showed promising efficacy against gastric cancer (GC) a preclinical study. Here we report interim analysis results an ongoing, open-label, single-arm, phase 1 clinical trial CLDN18.2-targeted (CT041) patients with previously treated, CLDN18.2-positive digestive system cancers ( NCT03874897...
Abstract Purpose RC48 contains the novel humanized anti-HER2 antibody hertuzumab conjugated to MMAE via a cleavable linker. A phase I study was initiated evaluate toxicity, MTD, PK, and antitumor activity of in patients with HER2-overexpressing locally advanced or metastatic solid carcinomas, particularly gastric cancer. Patients methods This 2-part study. Successive cohorts received escalating doses (0.1 mg/kg, 0.5 1.0 2.0 2.5 3.0 mg/kg). Dose expansion proceeded at dose mg/kg Q2W. The...
infection is associated with the risk of gastrointestinal (GI) cancers; however, its impact on immunotherapy for GI cancers remains uncertain. In this study, we included 10,122 patients who underwent
Epstein-Barr virus (EBV)-associated gastric cancer (GC) (EBVaGC) is a distinct molecular subtype of GC with favorable prognosis. However, the exact effects and potential mechanisms EBV infection on immune checkpoint blockade (ICB) efficacy in remain to be clarified. Additionally, EBV-encoded RNA (EBER) situ hybridization (ISH), traditional method detect EBV, could cause false-positive/false-negative results not allow for characterizing other biomarkers recommended by standard treatment...
Abstract Background A significant subset of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) gastric adenocarcinomas (GAC) are resistant to immune checkpoint inhibitors (ICIs), yet the underlying mechanism remains largely unknown. We sought investigate genomic correlates density tumor-infiltrating cells (DTICs) and primary resistance ICI treatment. Methods Four independent cohorts MSI-H GAC were included: (i) surgery cohort ( n = 175) with DTIC data, (ii) 3DMed 32)...
The sole use of single modality data often fails to capture the complex heterogeneity among patients, including variability in resistance anti-HER2 therapy and outcomes combined treatment regimens, for HER2-positive gastric cancer (GC). This deficit has not been fully considered many studies. Furthermore, application artificial intelligence predicting response, particularly diseases such as GC, is still its infancy. Therefore, this study aimed a comprehensive analytic approach accurately...
Background Despite the great achievements made in immune-checkpoint-blockade (ICB) cancer therapy, there are no effective predictive biomarkers gastrointestinal (GI) cancer. Methods This study included 93 metastatic GI patients treated with ICBs. The first cohort comprising 73 were randomly assigned into discovery (n=44) and validation (n=29) cohorts. Comprehensive genomic profiling was performed on all samples to determine tumor mutational burden (TMB) copy-number alterations (CNAs). A...
Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape of gastrointestinal cancer. However, biomarkers correlated with efficacy ICIs in cancer are still lacking. In this study, we performed 395-plex immune oncology (IO)-related gene target sequencing tumor samples from 96 patients metastatic treated ICIs, and a linear support vector machine learning strategy was applied to construct predictive model. ResultsAll were randomly assigned into discovery (n=72)...
Immune checkpoint inhibitors (ICIs) have dramatically improved survival in advanced gastrointestinal (GI) cancer patients, but also resulted immune-related adverse events (irAEs). This study aimed to evaluate serological biomarkers of irAEs and treatment response GI patients.Metastatic patients were enrolled between August 1, 2015, July 31, 2017. Serum samples collected at baseline, a panel 59 serum was tested. The occurrence analyzed, biomarker expression correlated with irAE incidence...
Background Gastrointestinal (GI) cancer is the second most common type with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) phenotype that expected to respond immune-checkpoint inhibitors (ICIs). However, approximately half of patients dMMR/MSI-H GI derive no benefit from ICIs. We sought identify predictors primary resistance ICIs in cancer. Methods Three independent cohorts were included: (1) discovery cohort (65 cancer) ICI efficacy data and pre-ICIs tissue samples...
Abstract The association between genetic variations and immunotherapy benefit has been widely recognized, while such evidence in gastrointestinal cancer remains limited. We analyzed the genomic profile of 227 immunotherapeutic patients treated with immunotherapy, from Memorial Sloan Kettering (MSK) Cancer Center cohort. A immune prognostic signature (GIPS) was constructed using LASSO Cox regression. Based on this signature, were classified into two subgroups distinctive prognoses ( p <...
Cr
Abstract Background Gastric cancer (GC) is confronted with limited options for precision medicine. Human epidermal growth factor receptor 2 (HER2) the principal druggable target of GC, yet proper biomarkers response/resistance prediction remain unveiled. Methods From 40 GC patients received HER2‐targeted therapy, a total 327 peripheral blood plasma specimens was collected including baseline and treatment time points. Circulating tumor DNA (ctDNA) extracted sequenced panel 425 genes....
Background Microsatellite instability (MSI) represents the first pan-cancer biomarker approved to guide immune checkpoint blockade (ICB) treatment. However its widespread testing, especially outside of gastrointestinal cancer, is hampered by tissue availability. Methods An algorithm for detecting MSI from peripheral blood was established and validated using clinical plasma samples. Its value predicting ICB efficacy evaluated among 60 patients with advanced cancer. The landscape in also...
Background Early onset colorectal cancer (EOCRC) is a heterogeneous subtype with obvious hereditary tendencies and increasing incidence. We sought to determine the susceptibility genes molecular characteristics of EOCRC. Methods 330 EO metastatic CRC (mCRC) (≤55 years) 110 average-onset (AO) mCRC patients (>55 were enrolled. Capture-based targeted sequencing was performed on tumor tissue paired white blood cells using panel 520 genes. The association between alterations overall survival (OS)...
Background: Combinatorial inhibition of epidermal growth factor receptor (EGFR) and BRAF shows remarkable clinical benefits in patients with V600E-mutant metastatic colorectal cancer (mCRC). However, the tumor may inevitably develop resistance to targeted therapy, thereby limiting response rate durability. This study aimed determine genetic alterations associated intrinsic acquired EGFR/BRAF inhibitors mCRC. Methods: Targeted sequencing 520 cancer-related genes was performed tissues plasma...
Biomarkers in non-colorectal gastrointestinal (GI) cancer patients receiving immune checkpoint blockades (ICBs) are still limited.Data were prospectively collected from a discovery cohort (n = 53) and validation 107) with GI ICB, as well chemotherapy-only 171). System inflammatory markers derived neutrophil-to-lymphocyte ratio (dNLR) determined biomarkers by univariate multivariate analyses.A higher level of dNLR (cutoff 3) was associated shorter overall survival (OS) cohorts. In pooled...